Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
08/28/2003 | WO2003070884A2 RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
08/28/2003 | WO2003070881A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
08/28/2003 | WO2003070823A2 Conjugates comprising a biodegradable polymer and uses therefor |
08/28/2003 | WO2003070805A1 Hydrolytically degradable alkylene oxide based polymers |
08/28/2003 | WO2003070775A1 Novel natural cyclodextrin complexes |
08/28/2003 | WO2003070772A1 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments |
08/28/2003 | WO2003070755A2 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier |
08/28/2003 | WO2003070750A2 Rna interference mediated inhibition of hepatitis c virus |
08/28/2003 | WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
08/28/2003 | WO2003070743A1 RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
08/28/2003 | WO2003070742A1 RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
08/28/2003 | WO2003070738A2 Topiramate salts and compositions comprising and methods of making and using the same |
08/28/2003 | WO2003070282A2 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
08/28/2003 | WO2003070281A1 Prostaglandin composition for the treatment of erectile dysfunction |
08/28/2003 | WO2003070280A2 Absorption enhancing agent |
08/28/2003 | WO2003070279A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
08/28/2003 | WO2003070273A1 A bioadhesive agent |
08/28/2003 | WO2003070272A1 An immunological adjuvant |
08/28/2003 | WO2003070227A1 Taste-masked film-type or wafer-type medicinal preparation |
08/28/2003 | WO2003070226A1 Edible pga coating composition |
08/28/2003 | WO2003070223A1 Sustained release preparations and process for producing the same |
08/28/2003 | WO2003070222A1 Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents |
08/28/2003 | WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
08/28/2003 | WO2003070218A1 Sustained-release ointment for topical administration |
08/28/2003 | WO2003070217A1 Levothyroxine compositions and methods |
08/28/2003 | WO2003070177A2 Use of melatonin analogues for induction of general anesthesia |
08/28/2003 | WO2003070174A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
08/28/2003 | WO2003070173A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
08/28/2003 | WO2003070153A2 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives |
08/28/2003 | WO2003069998A1 Stable compositions comprising tezacitabine |
08/28/2003 | WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
08/28/2003 | WO2003057359A3 Microparticles and methods for their production |
08/28/2003 | WO2003053158A3 Malleable protein matrix and uses thereof |
08/28/2003 | WO2003047629A3 Treatment of diseases via the skin |
08/28/2003 | WO2003041690A3 Three-dimensional suspension printing of dosage forms |
08/28/2003 | WO2003041683A3 Orodispersible tablets containing fexofenadine |
08/28/2003 | WO2003037384A3 Polymer conjugates of protein kinase c inhibitors |
08/28/2003 | WO2003035044A3 Production of starch-gel-based shaped bodies |
08/28/2003 | WO2003035026A3 Polysaccharide-based network and method for the production thereof |
08/28/2003 | WO2003031467A3 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
08/28/2003 | WO2003024454A3 Topical composition containing brucine and the use for the treatment of damaged mammalian skin |
08/28/2003 | WO2003022071A3 Colorant for food and pharmaceuticals |
08/28/2003 | WO2003017990A3 Ophthalmic composition comprising an ascomycin |
08/28/2003 | WO2003016522A3 Methods and compounds for the targeting of protein to exosomes |
08/28/2003 | WO2003015656A3 Oral care substance delivery strip |
08/28/2003 | WO2003011239A3 Sunscreen composition |
08/28/2003 | WO2003008932A3 Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols |
08/28/2003 | WO2003000738A3 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
08/28/2003 | WO2002058622A3 Sn-38 lipid complexes and methods of use |
08/28/2003 | WO2002043771A3 Conjugates of glycosylated/galactosylated peptide |
08/28/2003 | WO2002041921A3 Compositions for protection against bovine viral diseases |
08/28/2003 | WO2002032914A3 Acylated cellobiose compounds |
08/28/2003 | WO2002015885A3 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
08/28/2003 | WO2002005800A9 Compositions for sustained release of analgesic agents, and methods of making and using the same |
08/28/2003 | WO2002000839A3 Statement as to federally sponsored research |
08/28/2003 | WO2001085147A3 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF |
08/28/2003 | US20030162953 Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
08/28/2003 | US20030162948 Tumour necrosis factor binding ligands |
08/28/2003 | US20030162841 Biocompatible crosslinked polymers |
08/28/2003 | US20030162835 Method of making particles for use in a pharmaceutical composition |
08/28/2003 | US20030162821 Applying topical mixtures of allantoin, emulsifiers and optionally steroids, nonsteroidal antiinflammatory agents, leukotriene antagonists or monoclonal antibodies, to prevent scarring, ulcers or blisters on skins |
08/28/2003 | US20030162751 Pharmaceutical composition comprising 5' monophosphate ester of riboflavin and solubilized riboflavin |
08/28/2003 | US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen |
08/28/2003 | US20030162739 Antisense molecules and method of controlling expression of gene function by using the same |
08/28/2003 | US20030162726 Sugar-free products with improved characteristics |
08/28/2003 | US20030162721 Anticancer agents; bioavailability; sustained release |
08/28/2003 | US20030162719 Immobilization of active materials |
08/28/2003 | US20030162711 Pharmaceutical formulation |
08/28/2003 | US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains |
08/28/2003 | US20030162693 Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
08/28/2003 | US20030161957 Impregnating polymer with active ingredient solution, adding compressed fluid until precipitation of active ingredient caused by compressed fluid antisolvent effect, removing the solvent and compressed fluid; drug delivery |
08/28/2003 | US20030161895 Comprising water, Xanthan gum, Magnesium aluminum silicate, Kaolin, Silicon dioxide, Sodium sulfacetamide, Sodium thiosulfate, Glyceryl stearate, PEG-100 Stearate, Quillaia saponaria extract, Benzyl alcohol, sulfur, high sorption base |
08/28/2003 | US20030161888 Pharmaceutical Composition |
08/28/2003 | US20030161885 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
08/28/2003 | US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
08/28/2003 | US20030161883 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis |
08/28/2003 | US20030161873 Method for stabilizing preparation |
08/28/2003 | US20030161871 Intensifying water solubility of vitamin B12 using solubilizers such as complexing agents, liposomes, oils, surfactants, cosolvents or (micro)emulsions; multicompartment drug delivery kits |
08/28/2003 | US20030161870 Dual enhancer composition for topical and transdermal drug delivery |
08/28/2003 | US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition |
08/28/2003 | US20030161858 Mixtures of cement powders, vitamins, hormones, antibiotics, antitumor agents, somatotropins, calcium phosphates or proteins dissolved, dispersed or emulsified in oils; bone disorders |
08/28/2003 | US20030161846 Oral administration of an emulsion pre-concentrate of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat; forms an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability |
08/28/2003 | US20030161837 Crosslinking an immunoglobulin or fragment thereof with anN-hydroxyl-succinimide ester and a maleimide linked vis a polyethyleneoxide spacer and incubating with a polypeptide having a sulfhydryl group (an allergen or autoantigen) |
08/28/2003 | US20030161809 Complexes; drug delivery |
08/28/2003 | US20030161791 Water-soluble polymer conjugates of retinoic acid |
08/28/2003 | US20030159953 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof |
08/28/2003 | DE29924428U1 New topical composition for treating herpes family viruses, reduces treatment-related erythema but maintains high activity |
08/28/2003 | CA2477321A1 Absorption enhancing agent |
08/28/2003 | CA2477191A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
08/28/2003 | CA2477068A1 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
08/28/2003 | CA2476958A1 An immunological adjuvant |
08/28/2003 | CA2476834A1 Natural cyclodextrin complexes of cannabinoids |
08/28/2003 | CA2476626A1 Microparticles with adsorbed polypeptide-containing molecules |
08/28/2003 | CA2476452A1 Electroporation methods for introducing bioactive agents into cells |
08/28/2003 | CA2476423A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
08/28/2003 | CA2476422A1 Topiramate salts and compositions comprising and methods of making and using the same |
08/28/2003 | CA2476402A1 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives |
08/28/2003 | CA2476380A1 Stable compositions comprising tezacitabine |
08/28/2003 | CA2476112A1 Rna interference mediated inhibition of interleukin gene expression using short interfering nucleic acid (sina) |
08/28/2003 | CA2475923A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |